Genomma Lab Internacional, S.A. (LABB) Fair Value & Analysis

Healthcare · MX · Market cap 14.7B MXN

Price vs Fair Value (12 months)

12‑month range 14.13 MXN – 22.16 MXN · fair‑value band 27.24 MXN – 45.39 MXN · the 14.95 MXN price screens below the 36.32 MXN fair value. As of Jul 16, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Genomma Lab Internacional, S.A. (LABB) currently trades at 14.95 MXN, while our model-based Fair Value estimate is 36.32 MXN, implying the stock looks roughly 142.9% undervalued today. We read business quality at 52/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, Genomma Lab Internacional, S.A. generated revenue of 17.3B MXN at a net margin of 9.3%. Revenue declined 4.9% year over year. It earns a return on equity of 14.1%. Net debt stands at 1.7B MXN. Fundamentals as of Jul 16, 2026

Our scenario range runs from 27.24 MXN (bear case) to 45.39 MXN (bull case); at 14.95 MXN, the current price sits below that range. The share trades about 35% below its 52-week high and 2% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -44% fair-value upside, at 143%, LABB screens cheaper than that median.

Key figures & financial health

About the company

Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hair loss, ointment for muscle pain, anti-fungal treatments for the relief of colitis, products to counter stress levels, anti-wrinkles, antacids, anti-ulcers, anti-flu, protection and improvement products, treatments against hemorrhoids, against varicose veins, osteoarthritis, ophthalmic medications, infant nutrition, and others. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Genomma Lab Internacional, S.A. reported revenue of 17.5B MXN in FY2025 versus 15.5B MXN in FY2021, a compound +3.2%/yr. Reported net income was 1.6B MXN in FY2025, compounding +5.4%/yr from FY2021.

Is LABB fairly valued? → Check now

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.